The Exploration of Vetiver (Vetiveria zizanioides) as Co-Chemotherapy of Lung Cancer Selectively Targets AKR1C1: Bioinformatics Approach

Lucky Octavianus Saputra, Salsabila Yusfita Fawzy, Ratih Kurnia Wardani, Endang Lukitaningsih


Reactive Oxygen Species (ROS) is one of the cancer-causing agents, one of which is lung cancer. In addition to being carcinogenic, ROS can also be used to kill cancer cells themselves, by increasing their levels to the threshold of apoptosis. Therefore, it is necessary to inhibit certain antioxidant enzymes that are highly expressed in lung cancer. One of them is AKR1C1 which plays a role in the eradication of intracellular ROS. However, AKR1C1 has a high structural similarity to AKR1C2, so it can inhibit therapy causing selectivity problems. Vetiver (Vetiveria zizanioides) has potential as an anticancer. This study was conducted to explore vetiver as a co-chemotherapeutic agent for lung cancer targeting AKR1C1 selectively. The method used is distillation, identification of vetiver compounds using GC-MS, and through bioinformatics studies. Predictive analysis with KNIME was carried out to determine the activity of the test compound. All tested vetiver compounds had a predictive value of 1 (active) on AKR1C1 and 0 (inactive) on AKR1C2. Through GC-MS obtained 354 compounds were identified. These compounds are used to filter the compounds predicted by KNIME. The molecular docking results showed that of the 10 tested vetiver compounds, there was 1 compound that had the strongest bond in interacting with AKR1C1, namely beta vetispirene compound with an S-score of -15.12 kcal/mol, and stronger than native ligand and aspirin. Based on the research data, it can be concluded that the beta vetispirene compound in vetiver can be a potential co-chemotherapy agent for lung cancer in targeting AKR1C1 selectively. However, further research is needed to prove its activity on lung cancer cells.

Keywords: ROS (Reactive Oxygen Species), Lung Cancer, AKR1C1, selectivity, vetiver (Vetiveria zizanioides).

Full Text:



Brozic, P., Smuc, T., Gobec, S., and Rizner, T.L., 2006, Phytoestrogens as inhibitors of the human progesterone metabolizing enzyme AKR1C1, Mol. Cell. Endocrinol., 259(1-2), 30–42. CrossRef

Beisken, S., Meinl, T., Wiswedel, B., De Figueiredo, L. F., Berthold, M., and Steinbeck, C., 2013, KNIME-CDK: Workflow-driven Cheminformatics, BMC Bioinformatics., 14, 257. CrossRef

Chitra, T., Jayashee, S., and Rathinamala, J., 2014, Evaluation of anticancer activity of Vetiveria Zizanioides against human breast cancer cell line, International Journal of Pharmacy and Pharmaceitocal Sciences., 6(1), 164-166.

Cima, F., and Ballarin, L,. 2021, Genotoxicity and Immunotoxicity of Organotins, Biochemical and Biological Effects of Organotins., 15, 97-111.

Cruz, C.S.D., Tanoue, L.T., and Matthay, R.A., 2011, Lung Cancer: Epidemiology, Etiology, and Prevention, Clinics in chest medicine, 32(4), 605-644. CrossRef

Deng, G., David, A., Wang, F., Sun, X., Li, H., Lin, J., and Li, P., 2019, Chemical Composition, Antioxidant, and Antimicrobial Activities of Vetiveria zizanoides (L.) Nash Essential Oil Extracted by Carbon Dioxide Expanded Ethanol, Molecules., 24(10), 1897. CrossRef

Gašparović, A., 2020, Free Radical Research in Cancer, Antioxidants., 9(2), 157. CrossRef

Issaravanich, S., Palanuvej, C., Tunsaringkarn, T., Rungsiyothin, A., Vipunngeun, A., Chuthaputti, A., and Ruangrungsi, N., 2008, Pharmacognosic specification of Vetiveria zizaniodes roots in Thailand, J Health Res., 22(1), 9-14. Link

Larasati, Y.A., Kato, N.Y., Nakamar, I., Yokoyama, T., Meiyanto, E., and Kato, J.Y., 2018, Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth, Scientific Reports., 8(1), 2039. CrossRef

Meiyanto, E., and Jenie, R.I., 2007, Ko-kemoterapi ekstrak etanolik daun sambung nyawa (Gynura procumbens (Lour.) Merr.) dan Doxorubicin pada sel kanker payudara, Majalah Farmasi Indonesia, 18(2), 81-87. CrossRef

Tian, H., Li, X., Jiang, W., Lv, C., Sun, W., Huang, C., and Chen, R., 2016, High expression of AKR1C1 is associated with proliferation and migration of small-cell lung cancer cells, Lung Cancer: Targets and Therapy., 7, 53–61. CrossRef

Wenners, A., Hartmann, F., Jochens, A., Roemer, A.M., Alkatout, I., Klapper, W., Mackelenbergh, M. V., Mundhenke, C., Jonat, W., and Bauer, M., 2016, Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer, Int. J. Clin. Oncol., 21, 548–556. CrossRef

Zeng, C.M., Chang, L.L., Ying, M.D., Cao, J., He, Q.J., Zhu, H. and Yang, B., 2017, Aldo–Keto Reductase AKR1C1–AKR1C4: Functions, Regulation, and Intervention for Anti-cancer Therapy, Frontiers in Pharmacology, 8, 119. CrossRef


Copyright (c) 2022 Endang Lukitaningsih, Lucky Octavianus Saputra, Salsabila Yusfita Fawzy, Ratih Kurnia Wardani

Indexed by:




Indonesian Society for Cancer Chemoprevention